Page 193 - Aet News Today

Drs. Carolyn Bertozzi, Barry Sharpless, and Morten Meldal shared the 2022 Nobel Prize in Chemistry for greatly simplifying the synthesis of complicated molecules. Dr. Bertozzi's protégé writes why her research is so important.

Two Congresspeople recently introduced a bill seeking to terminate the VA's Oracle Cerner EHR rollout. The legislation said that the project is too flawed and costly to carry on — the lawmakers called for VA facilities to revert back to the department’s internally developed EHR.

Karuna Therapeutics has licensed two small molecules that shuttering Goldfinch Bio had developed for kidney disorders. These compounds target a pathway that could also treat neurological disorders, giving clinical-stage Karuna the opportunity to compete against a drug candidate from Boehringer Ingelheim.

Orserdu, a drug from Menarini Group subsidiary Stemline Therapeutics, is now approved for treating breast cancers that carry the ESR1 mutation. The drug is the first approved oral therapy from a class of therapies called selective estrogen receptor degraders (SERDS).

Season one focusing on chronic disease management kicks off with a conversation with Stephanie Tilenius, CEO of VIda Health that aims to treat both the mind and the body.

Point solutions for areas like behavioral health, family planning and more have risen in popularity in recent years, experts said. But as employers deal with point solution fatigue, healthcare navigation companies are proving beneficial.

Security threats are not going away any time soon. In fact, they are on the rise and likely will be for years to come. Here are three ways to solve the most pressing problems.

Instead of leaning on the arbitrary and subjective nature of prominent, perceived prestige-focused industry rankings, health systems must shift to a data-driven and mathematically sound approach to determining and benchmarking quality.

The final rule calls for stricter audits on Medicare Advantage plans. AHIP president and CEO Matt Eyles referred to the rule as "unlawful and fatally flawed."

Paradigm, a new startup co-incubated by ARCH Venture Partners and General Catalyst, recently launched with $203 million in Series A funding. The company is focused on improving equitable access to trials by creating a less fragmented and more efficient clinical research ecosystem.